Menu
Recruiting NCT06544720

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

Phase I Interventional Human Papillomavirus Associated Carcinomas Cervical Cancer Head and Neck Cancers Anal Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: SCG142 TCR-T cells.
Who it may be relevant to
Registry conditions: Human Papillomavirus Associated Carcinomas, Cervical Cancer, Head and Neck Cancers, Anal Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas

Overview

A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Interventions

  • Biological SCG142 TCR-T cells
    Monotherapy of SCG142

Primary outcome measures

  • DLT [Time frame: 28 days]
Secondary outcome measures (1)
  • Efficacy: antitumor activity of SCG142 [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Greater than or equal to 18 years of age
  • HPV associated carcinomas
  • Patients must have at least one measurable lesion defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion criteria

  • Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
  • Patients with active autoimmune diseases.
  • Patient has a known active Hepatitis B or Hepatitis C.
  • Other severe medical conditions that may limit subject\'s participation in this trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The affiliated hosptial of qingdao university — Qingdao

Identifiers

NCT: NCT06544720 · SCG142-CI-101

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗